Background: Chemotherapy-induced febrile neutropenia (FN) is a clinically important complication that affects patient outcome by delaying chemotherapy doses or reducing dose intensity. Risk of FN depends on chemotherapy-and patient-level factors. We sought to determine the effects of chronic comorbidities on risk of FN.
introduction Chemotherapy-induced febrile neutropenia (FN) is a clinically important complication that can impact patient treatment outcomes and often incur a significant health care cost [1] . Previous studies have found that prophylactic granulocyte colony-stimulating factor (G-CSF) was cost-effective when used among patients at high risk for FN [2] . In the past decade, risk stratification for FN has progressed from a chemotherapy regimen-based algorithm to one that incorporates patient characteristics [3] . A few studies have suggested that chronic comorbidities can also influence the risk of FN. Specifically, a history of heart and renal disease has been linked to increased risk of FN in NHL patients [4] . However, there are limited data regarding the effects of other chronic comorbidities on the risk of FN or severe neutropenia. To understand the effects of chronic comorbidities on risk of chemotherapy-induced neutropenia, we conducted a retrospective cohort study of patients diagnosed with six types of cancer in Kaiser Permanente Southern California (KPSC) to examine the association between a wide variety of chronic comorbidities and the risk of neutropenia and FN in the first cycle of chemotherapy among patients who are not already receiving prophylactic G-CSF.
methods study setting and population KPSC is an integrated managed care organization that provides comprehensive health services for 3.5 million racial/ethnically and socioeconomically diverse enrollees who are broadly representative of residents in Southern California [5] . KPSC maintains a number of electronic clinical records for virtually all aspects of care delivered, including diagnoses in the form of International Classification of Diseases (ICD)-9 codes, medical procedures, pharmacy dispensing, laboratory test results and disease registries, all linkable through a unique member identifier. Incident cancer cases were identified using KPSC's Surveillance, Epidemiology, and End Results (SEER)-affiliated cancer registry. KPSC's cancer registry routinely collects information on age at diagnosis, sex, race/ethnicity, cancer histology, site, stage, and initial cancer treatment. The quality of the cancer registry data is assured by the SEER standard.
The study cohort was composed of patients who met the following inclusion criteria: (i) diagnosed with incident non-Hodgkin lymphoma (NHL), breast cancer, colorectal cancer, lung cancer, ovarian cancer, or gastric cancer at KPSC between 2000 and 2009; (ii) aged 18 years and older at cancer diagnosis; iii) received chemotherapy within 12 months of cancer diagnosis; and (iv) had at least 12 months of KPSC membership before cancer diagnosis (to ensure sufficient medical records exist to allow assessment of comorbidities of interest). Of those who met the inclusion criteria, we further excluded subjects who met the following criteria: (i) unknown cancer stage or for whom chemotherapy agents could not be identified; (ii) received prophylactic G-CSF defined as use within 4 days after the first chemotherapy administration, including those on dose-dense chemotherapy regimens; (iii) had bone marrow or stem cell transplantation (as identified by CPT 38 204-38 242); or (iv) were patients of Orange County Medical Center if their cancer was diagnosed before 2007. This last criterion was used because laboratory data on absolute neutrophil count could not be readily extracted electronically for this medical center before 2007.
exposure of interest
The main exposure of interest in this study was the history of chronic comorbidities at the time of cancer diagnosis. Comorbidities of interest included diabetes mellitus, diabetes mellitus with end organ damage, hypertension, obesity, myocardial infarction, congestive heart failure (CHF), peripheral vascular disease, cerebrovascular disease, thromboembolic events, chronic obstructive pulmonary disease (COPD), previous cancer, liver disease (hepatitis, cirrhosis), renal failure, rheumatoid disease, other autoimmune conditions, thyroid disorder, peptic ulcer disease, osteoarthritis, connective tissue disease, HIV infection, and acquired immunodeficiency syndrome (AIDS). We also considered a person's total number of comorbidities (those listed above, except obesity). A bone marrow suppression score (BMSS) was also created based on the presence of the following conditions at study baseline: anemia (1 point if prior diagnosis of anemia or hemoglobin <10 g/dl), neutropenia [1 point if 1500< absolute neutrophil count (ANC) ≤1000/µl, 2 points if ANC <1000/µl], and thrombocytopenia (1 point if platelet count <75 000/μl).
The history of most comorbidities was assessed using ICD-9 diagnosis coding dating back to 12 months before cancer diagnosis. Diabetes, prior cancer, and HIV infection were identified using KPSC's pre-established case identification system or disease registries. Details for comorbidity identification methods can be found in supplementary Table S1 , available at Annals of Oncology online. For diabetes, hypertension, and rheumatoid arthritis, subsets of more severe cases defined as those who received prescription treatments for these conditions, were also assessed.
outcomes of interest
The primary outcome of interest in this study was FN. Secondary outcomes of interest included grade III and IV neutropenia combined, and grade IV neutropenia alone. FN was defined as having combinations of ICD-9 codes or laboratory values using one of the following methods: neutropenia (ICD-9 code 288.0) and fever (ICD-9 code 780.6) on the same day; ANC <1000/µl and fever (ICD-9 code 780.6) within 7 days; hospitalization with neutropenia (ICD-9 code 288.0) as the primary diagnosis; or neutropenia (ICD-9 code 288.0) or ANC <1000/µl and hospitalization with bacterial/fungal infection (identified from ICD-9 codes) within 7 days. Grade III neutropenia was defined as an ANC from ≥500 to <1000/µl, and grade IV neutropenia was defined as an ANC <500/µl. All three outcomes were assessed only in the first chemotherapy cycle to allow the most unbiased assessment of the effect of a comorbidity on the risk of neutropenia. Patients were followed up for a maximum of 28 days after the first chemotherapy administration, the beginning of the second cycle of administration, termination of KPSC membership, death, or the neutropenic event of interest, whichever came first.
other covariates of interest
Patient characteristics that were included in this analysis included age at cancer diagnosis, sex, race/ethnicity, census block income and education level, public insurance status, i.e. Medicare or Medicaid enrollment, and length of KPSC membership. Cancer and treatment characteristics considered in this analysis included stage at diagnosis and cancer treatment, i.e. radiation therapy and chemotherapy regimen. Chemotherapy regimens were categorized based on its risk of inducing FN into highly myelosuppressive (>20% risk of developing FN), moderately myelosuppressive (10%-20% risk of developing FN), or unclassified (<10% risk of developing FN and all other regimens not in these lists) [6] . Dose reduction was defined as having a relative dose intensity of <90% of the standard dose intensity. In addition to the FN risk group category of the chemotherapy regimen, we also considered the number of myelosuppressive agents in the regimen. Laboratory measures of interest included ANC at the time of cancer diagnosis, taken before the administration of chemotherapy. Risk factors that increase the risk of the comorbidities of interest were also captured; these included smoking and dyslipidemia.
statistical analysis
The distributions of demographics, cancer and treatment characteristics, and comorbid conditions were described. The occurrence of FN or grade III or IV neutropenia in the first cycle of chemotherapy was tabulated among all cancer patients (pooled) by comorbidity status. We carried out multivariable Cox regression to evaluate the association between chronic comorbidities and hazard of FN, grade III/IV (assessed as one outcome), or grade IV neutropenia. Given the small number of outcomes of interest and a large number of covariates, a propensity score was used to adjust for potential confounding factors. The propensity score for each comorbid condition of interest was estimated using logistic regression to model the probability that a patient would have a comorbid condition given all the potential confounders. In the multivariable Cox model, the following variables were included: comorbidity of interest and its propensity score (modeled as natural cubic splines with four degrees of freedom). Since the hazard for developing FN varies across cancer types, we estimated Cox models stratified by cancer type. As a sensitivity analysis, the multivariable Cox model also included covariates that were potential causal intermediates including cancer stage, baseline ANC (in linear form), chemotherapy regimen (high and intermediate risk versus unclassified risk), number of myelosuppressive agents that were dose reduced, number of myelosuppressive agents that were not dose reduced, radiation therapy before chemotherapy, and history of prior cancer (as a proxy for history of neutropenia), in addition to the comorbidity of interest and its propensity score. Prior cancer was not included in the Cox model when evaluating prior cancer as a comorbidity of interest. The analyses were clustered at the medical center level (where a cancer patient was treated) using robust sandwich estimate of the covariance matrix. We conducted cancer-type specific analyses and found little evidence for effect modification by cancer type. Thus, only results from pooled analyses are presented.
To evaluate how different comorbidities might interact to modify the risk of FN, two-way interaction terms were created and tested for the following pairs of comorbidities: diabetes and renal disease (severe diabetes/nephropathy), diabetes and obesity (diabetes predisposes to infections, but obesity minimizes the toxic effects of chemotherapy), and liver disease and renal
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results
A total of 62 714 patients were diagnosed with NHL or breast, colorectal, lung, ovarian, or gastric cancer from 2000 to 2009 at KPSC. After applying the inclusion and exclusion criteria, this study included 19 160 patients with these cancers (Figure 1 ) with a mean age of 60 years at diagnosis. Table 1 shows the characteristics of the study cohort overall and by cancer type. In the first chemotherapy cycle, 963 patients (5.0%) developed FN, 1892 patients (9.9%) developed grade III neutropenia, and 2134 patients (11.1%) developed grade IV neutropenia ( Table 2) . The incidence of all neutropenic outcomes appeared to be higher Breast n = 7127
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Had bone marrow transplant
Unknown cancer stage in patients who had HIV/AIDS, liver disease, peptic ulcer disease, autoimmune condition, and thyroid disorder than in patients who did not have these conditions. In the multivariable Cox model adjusting for propensity scores only, the following comorbid conditions were found to be positively associated with risk of FN, and grade III/IV neutropenia: HIV infection, liver disease, peptic ulcer disease, and thyroid disorder. Estimated hazard ratio (HR) of FN for these conditions were: 3.40, 95% confidence interval (1.90-5.63), 1.39 (0.81-2.20), 1.57 (1.05-2.26), and 1.32 (1.06-1.64), respectively ( Table 3 and severe neutropenia. Estimates from models also adjusting for cancer stage, ANC, other cancer treatment, prior history of cancer, chemotherapy regimen, and dose reduction were similar to those that adjusted for the propensity score only. When we examined total number of comorbidities, increased number of comorbidities was associated with increased risk of FN (Table 3 , bottom), but not grade III/IV neutropenia.
In the evaluation of interaction terms, we did not find significant interaction between diabetes and renal disease (P-value for interaction term = 0.86), and liver disease and renal disease 
discussion
In this cohort study of 19 160 patients with six types of cancer who were treated with chemotherapy, we found that history of several comorbid conditions may increase the risk of FN and/or severe neutropenic outcomes in the first cycle of chemotherapy. These included COPD, CHF, HIV infection/AIDS, liver disease, peptic ulcer disease, renal disease, thyroid disorder, diabetes in nonobese patients, and conditions (baseline anemia, neutropenia, and thrombocytopenia) related to bone marrow suppression. Previous studies of NHL patients have shown that heart disease, liver, or renal dysfunction were associated with an increased risk of FN [1, 4, 7] . We confirmed these associations in this larger group of patients, and furthermore, extend the findings in patients with other cancer types, including five solid tumors.
Based on the available evidence, it is plausible that FN risk is mediated through bone marrow suppression, impaired neutrophil and other immune cell function, disturbances of barrier function (skin/mucosal integrity), and availability of pathogenic microbes. CHF may impair neutrophil function via impaired release of oxygen radicals [8] . Diabetes impairs neutrophil function through defects in chemotaxis [9] , phagocytosis [10] , and [11] . Renal disease [12] , thyroid disease [13] , and autoimmune disease (via impaired neutrophil migration) [14] have also been shown to impair neutrophil function.
In addition to its effect on CD4+ T cells, it is recognized that HIV also destroys immune precursor cells and causes damage to the bone marrow, possibly resulting in neutropenia [15] . Numbers in bold represent statistical significant associations at P-value <0.05 level. a The following risk factors were included in the propensity score function for each comorbid conditions: age (modeled as natural cubic splines), sex, race/ethnicity, calendar year of diagnosis (modeled as natural cubic splines), length of KPSC membership (in linear form), public insurance status (Medicare enrollees and Medicaid enrollees), and socioeconomic indicators (including census track median annual household income: $0-25 000, $25 001-40 000, $40 001-60 000, $60 001-80 000, and >$80 000; and proportion of adults with a high school diploma or a higher degree in the census track: ≤50%, 51-75%, >75%). In addition to this common set of potential confounders, potential confounders specific to each condition, such as other predisposing comorbidities, were also chosen on the basis of the causal diagram specific to the comorbid condition. b For evaluating the effect of bone marrow suppression score, potential confounders were directly adjusted in the Cox model without the use of propensity score function. Potential confounders adjusted in these models included age, sex, race/ethnicity, calendar year of diagnosis, length of KPSC membership, public insurance status, socioeconomic indicators, smoking, dyslipidemia, and number of comorbidities. These potential confounders were modeled as described above.
Further, peptic ulcer disease likely increases the risk of FN through its effects on impaired barrier function in the gastrointestinal tract. COPD increases the risk of respiratory infection likely via impaired airway epithelial barrier function [16] , impaired bacterial flora [17] , and use of inhaled steroids [18] . In addition to individual comorbidities, we also found that total number of comorbidities was significantly associated with FN risk. A dose response relationship was suggested by the increasing trend of HR from one to two to three or more comorbidities in comparison to absence of any comorbidity. These results are consistent with that reported by Hosmer et al. among patients with breast, lung, colorectal, and prostate cancer [19] , and by Grønberg et al. among patients with lung cancer [20] . Despite the consistent association between total comorbidity and FN, both we and Grønberg et al. [20] did not find an association between total number of comorbidities and risk of overall neutropenia. These results suggest that many comorbidities may exert their effects on FN through one or more of the other discussed mechanisms (impaired neutrophil function, impaired barrier function, and/or altered flora) instead of directly predisposing to neutropenia.
We observed a significant inverse association between obesity and risk of FN, grade III and IV neutropenia, which is consistent with the literature [21] [22] [23] . Potential mechanisms through which obesity may confer protection from chemotherapyinduced toxicity include altered pharmacokinetics and/or reduced relative efficacy of chemotherapy in obese patients. Our results provide additional assurance that obese patients are not at increased risk of FN, which may have implications for chemotherapy dose adjustment for these patients.
There are several limitations that should be considered when interpreting the results of this study. First, because NCCN guidelines recommend that patient comorbidities, especially liver and renal dysfunction, are taken into consideration when estimating the overall risk of FN [8] , the subset of patients who were included in these analyses may have had fewer severe comorbid conditions and may be less likely to have FN than the overall patient population. Second, a total of 202 (1%) of the subjects had G-CSF use beyond day 4 of chemotherapy administration, some of which might be as prophylactic use. However, given the small proportion of these patients, this is unlikely to materially affect our results. Another limitation to consider is that we did not adjust for multiple comparisons. Due to the large numbers of associations examined, some of the statistically significant associations may be due to chance; however, most of these associations showed consistent trends across the three neutropenic outcomes. Our study may also have misclassification in the ascertainment of the comorbid conditions and FN using ICD-9 diagnosis codes.
In conclusion, in this study, we found that history of several comorbidities, including bone marrow suppression (pre-existing anemia, thrombocytopenia, and/or neutropenia), COPD, CHF, HIV infection/AIDS, liver disease, peptic ulcer disease, renal disease, autoimmune disease, and thyroid disorder may increase the risk of developing FN or severe neutropenia in patients treated with chemotherapy. Obese patients had decreased risk of FN/neutropenia. If confirmed by others, these results may assist FN risk stratification for cancer patients, and should be considered when making decisions regarding treatment choices and the use of prophylactic G-CSF. references
